Actively Recruiting
Comparing Standard and Adaptive Dosing of Lutetium 177Lu PSMA Radioligand Therapy in Men with Advanced Metastatic Castration-Resistant Prostate Cancer
Led by Alliance for Clinical Trials in Oncology · Updated on 2026-11-03
1524
Participants Needed
142
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether adjusting the timing of doses for the prostate cancer drug lutetium 177 Lu PSMA RLT can improve quality of life without shortening lifespan in patients with hormone-resistant prostate cancer that has spread locally or to distant sites. This phase III trial compares the standard fixed 6-week dosing schedule to an adaptive schedule where treatment intervals may be lengthened based on disease activity. The study focuses on men with metastatic castration-resistant prostate carcinoma who have tumors expressing the PSMA protein. Participants initially receive two cycles of lutetium 177 Lu PSMA RLT intravenously, repeated every 6 weeks. Those showing a significant PSA decline then enter randomization one group continues the standard dosing every 6 weeks for up to four additional cycles, while the other group undergoes PSA monitoring every three weeks and receives treatment only when specific PSA or clinical progression criteria are met, allowing for adaptive dosing. Throughout the trial, patients undergo blood tests, CT scans, bone scans, and PSMA PET imaging at screening, with MRI scans for those with brain metastases or clinical indications. During the study, participants are monitored regularly with blood samples and imaging to assess disease progression and treatment effects. Quality of life is measured using standardized questionnaires over 30 months, and survival is tracked for up to five years. Follow-up visits occur every 12 weeks after treatment completion until disease progression, then every six months for up to five years. Researchers also evaluate treatment toxicity, pain severity, PSA response, and other health outcomes to compare the adaptive and standard dosing approaches.
CONDITIONS
Brief Title
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
Research Team
S
Shiva Baghaie, MPH
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here